Tirzepatide in Australia — Patient Information

About Tirzepatide in Australia

Tirzepatide is a prescription-only medicine in Australia, supplied under the brand name Mounjaro. Australian regulations restrict advertising of prescription medicines to consumers, so this page is general patient information about the medicine, the kind of consultation involved in being prescribed it, and the questions to discuss with an AHPRA-registered prescriber — not an advertisement, not an offer of sale, and not medical advice. Whether tirzepatide is suitable for an individual patient is a clinical decision following an assessment by a registered prescriber.

TGA-approved indication

In Australia, tirzepatide is TGA-approved for weight management in adults who meet the clinical criteria set out in its Australian Register of Therapeutic Goods entry. Suitability is determined by an AHPRA-registered prescriber on a case-by-case basis after a clinical assessment.

What to discuss with an AHPRA-registered prescriber

• Whether tirzepatide is clinically appropriate for your circumstances, given other medicines and conditions.
• The dose-escalation schedule and how long the treatment course is expected to be.
• Monitoring requirements, including any blood tests or follow-up reviews.
• Side effects, contraindications and what to do if you experience them.
• What happens if you need to stop the treatment.

Service-level cost components

Private prescription care in Australia generally involves the following cost components. The medicine itself is priced by the dispensing pharmacy — ask the prescriber and pharmacy for a written breakdown before paying.

• Consultation fee

  In-person and telehealth consultation fees vary by provider. Medicare rebates may apply where a Medicare item number is used.

• Prescription / clinical assessment

  May be bundled into the consultation or charged separately by the provider.

• Pharmacy dispensing

  Private dispensing fees vary by pharmacy. Cold-chain delivery may apply for refrigerated medicines.

• Follow-up reviews

  How often the prescriber reviews progress; the frequency affects the total cost of care.

• Programme model

  Some telehealth services bundle consultation, follow-up and dispensing into a monthly programme fee; others charge per item.

PBS and Medicare context

Tirzepatide is not currently PBS-subsidised in Australia, so the cost of the medicine is generally paid privately. Medicare may rebate part of the consultation cost where a Medicare item number is used by an eligible practitioner; Medicare does not subsidise the medicine itself for weight management. Check the current PBS schedule at pbs.gov.au.

FAQs